NYSE:HAE

Haemonetics Stock Forecast, Price & News

$62.53
+3.82 (+6.51 %)
(As of 06/17/2021 12:00 AM ET)
Add
Compare
Today's Range
$59.17
$62.64
50-Day Range
$51.81
$118.56
52-Week Range
$49.26
$142.11
Volume846,972 shs
Average Volume743,036 shs
Market Capitalization$3.19 billion
P/E Ratio40.34
Dividend YieldN/A
Beta0.36
30 days | 90 days | 365 days | Advanced Chart
Receive HAE News and Ratings via Email

Sign-up to receive the latest news and ratings for Haemonetics and its competitors with MarketBeat's FREE daily newsletter.


Haemonetics logo

About Haemonetics

Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, the company offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

2.16 out of 5 stars

Medical Sector

34th out of 2,100 stocks

Surgical & Medical Instruments Industry

3rd out of 174 stocks

Analyst Opinion: 4.4Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 2.5 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Haemonetics (NYSE:HAE) Frequently Asked Questions

Is Haemonetics a buy right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Haemonetics in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Haemonetics stock.
View analyst ratings for Haemonetics
or view top-rated stocks.

What stocks does MarketBeat like better than Haemonetics?

Wall Street analysts have given Haemonetics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Haemonetics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Haemonetics?

Haemonetics saw a increase in short interest during the month of May. As of May 28th, there was short interest totaling 2,380,000 shares, an increase of 28.0% from the May 13th total of 1,860,000 shares. Based on an average daily trading volume, of 988,000 shares, the days-to-cover ratio is currently 2.4 days. Approximately 4.7% of the shares of the company are sold short.
View Haemonetics' Short Interest
.

When is Haemonetics' next earnings date?

Haemonetics is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Haemonetics
.

How were Haemonetics' earnings last quarter?

Haemonetics Co. (NYSE:HAE) issued its quarterly earnings results on Thursday, May, 13th. The medical instruments supplier reported $0.46 EPS for the quarter, missing analysts' consensus estimates of $0.67 by $0.21. The medical instruments supplier earned $225 million during the quarter, compared to analysts' expectations of $223.92 million. Haemonetics had a net margin of 9.13% and a trailing twelve-month return on equity of 17.70%. Haemonetics's revenue was down 5.7% on a year-over-year basis. During the same quarter last year, the company posted $0.69 earnings per share.
View Haemonetics' earnings history
.

How has Haemonetics' stock price been impacted by Coronavirus?

Haemonetics' stock was trading at $103.72 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, HAE stock has decreased by 39.7% and is now trading at $62.53.
View which stocks have been most impacted by COVID-19
.

What guidance has Haemonetics issued on next quarter's earnings?

Haemonetics updated its FY 2022 earnings guidance on Tuesday, June, 8th. The company provided earnings per share (EPS) guidance of $2.600-3.000 for the period, compared to the Thomson Reuters consensus estimate of $3.480. The company issued revenue guidance of $983.62 M-1.03 billion, compared to the consensus revenue estimate of $1.02 billion.

What price target have analysts set for HAE?

9 brokerages have issued twelve-month price objectives for Haemonetics' stock. Their forecasts range from $71.00 to $155.00. On average, they anticipate Haemonetics' share price to reach $94.14 in the next twelve months. This suggests a possible upside of 50.6% from the stock's current price.
View analysts' price targets for Haemonetics
or view top-rated stocks among Wall Street analysts.

Who are Haemonetics' key executives?

Haemonetics' management team includes the following people:
  • Mr. Christopher A. Simon, CEO, Pres & Director (Age 57, Pay $2.53M)
  • Mr. William P. Burke, CFO & Exec. VP (Age 53, Pay $1.1M)
  • Ms. Michelle L. Basil, Exec. VP, Gen. Counsel & Sec. (Age 49, Pay $968.85k)
  • Ms. Jacqueline D. Scanlan, Sr. VP of HR (Age 47, Pay $792.1k)
  • Mr. Josep Lluis Llorens, Sr. VP of Global Manufacturing & Supply Chain (Age 59, Pay $826.89k)
  • Mr. Dan Goldstein, Principal Accounting Officer, VP & Corp. Controller (Age 44)
  • Ms. Anila Lingamneni, Exec. VP & Chief Technology Officer (Age 54)
  • Ms. Olga Guyette, Director of Investor Relations
  • Carla Burigatto, VP of Communications
  • Mr. Francis Tan, Sr. VP of Corp. Devel. & Planning

What is Christopher Simon's approval rating as Haemonetics' CEO?

48 employees have rated Haemonetics CEO Christopher Simon on Glassdoor.com. Christopher Simon has an approval rating of 63% among Haemonetics' employees. This puts Christopher Simon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Haemonetics' key competitors?

What other stocks do shareholders of Haemonetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Haemonetics investors own include NVIDIA (NVDA), Micron Technology (MU), Johnson & Johnson (JNJ), AbbVie (ABBV), Citigroup (C), Align Technology (ALGN), (APA), Chipotle Mexican Grill (CMG), Netflix (NFLX) and Pfizer (PFE).

What is Haemonetics' stock symbol?

Haemonetics trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."

Who are Haemonetics' major shareholders?

Haemonetics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.44%), Neuberger Berman Group LLC (5.58%), Franklin Resources Inc. (3.67%), Renaissance Technologies LLC (2.52%), London Co. of Virginia (2.08%) and Eaton Vance Management (2.04%). Company insiders that own Haemonetics stock include Anila Lingamneni, Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Mark W Kroll, Michelle L Basil, Richard J Meelia, Ronald G Gelbman, Said Bolorforosh and William P Mr Burke.
View institutional ownership trends for Haemonetics
.

Which institutional investors are selling Haemonetics stock?

HAE stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Credit Suisse AG, Royce & Associates LP, Waddell & Reed Financial Inc., Morgan Stanley, Point72 Asset Management L.P., Royal Bank of Canada, and Allianz Asset Management GmbH. Company insiders that have sold Haemonetics company stock in the last year include Anila Lingamneni, Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Mark W Kroll, Michelle L Basil, Richard J Meelia, and William P Mr Burke.
View insider buying and selling activity for Haemonetics
or view top insider-selling stocks.

Which institutional investors are buying Haemonetics stock?

HAE stock was purchased by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Principal Financial Group Inc., Principal Financial Group Inc., Assenagon Asset Management S.A., London Co. of Virginia, BlackRock Inc., Ameriprise Financial Inc., and Schroder Investment Management Group.
View insider buying and selling activity for Haemonetics
or or view top insider-buying stocks.

How do I buy shares of Haemonetics?

Shares of HAE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Haemonetics' stock price today?

One share of HAE stock can currently be purchased for approximately $62.53.

How much money does Haemonetics make?

Haemonetics has a market capitalization of $3.19 billion and generates $870.46 million in revenue each year. The medical instruments supplier earns $79.47 million in net income (profit) each year or $2.35 on an earnings per share basis.

How many employees does Haemonetics have?

Haemonetics employs 2,708 workers across the globe.

When was Haemonetics founded?

Haemonetics was founded in 1971.

What is Haemonetics' official website?

The official website for Haemonetics is www.haemonetics.com.

Where are Haemonetics' headquarters?

Haemonetics is headquartered at 125 Summer Street, Boston MA, 02110.

How can I contact Haemonetics?

Haemonetics' mailing address is 125 Summer Street, Boston MA, 02110. The medical instruments supplier can be reached via phone at 781-848-7100 or via email at [email protected]


This page was last updated on 6/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.